CHRONIC BACK PAIN: FROM PATHOGENETIC CONCEPTS TO THERAPEUTIC STRATEGIES
https://doi.org/10.21518/2079-701X-2017-17-36-42
Abstract
Social losses and expenses of healthcare resources related to chronic back pain continue remaining a high burden for the society. The mechanism of the central sensitization partially accounts for the formation of the chronic back pain, but these etiologic mechanisms of CNS dysfunction in this category of patients remain understudied. Of late more and more studies show that chronic neuroinflammation and aberrant activation of neuroglia are involved in formation and/or maintenance of the central sensitization. The work is focused on the analysis of the contribution of the inflammatory reactions in peripheral and central mechanisms of pain chronization in the back. General principles of chronic back pain are discussed, special attention is given to the possibility of target effect of etoricoxib on peripheral and central sensitization.
About the Author
O. V. Vorobieva
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
References
1. Bakker EW, Verhagen AP, van Trijffel E, Lucas C, Koes BW. Spinal mechanical load as a risk factor for low back pain: a systematic review of prospective cohort studies. Spine, 2009, 34: E281–293.
2. Modic MT, Ross JS. Lumbar degenerative disk disease. Radiology, 2007 Oct, 245(1): 43-61.
3. Pearce RH, Grimmer BJ, Adams ME. Degeneration and the chemical composition of the human lumbar intervertebral disc. J Orthop Res, 1987, 5(2): 198-205.
4. Samartzis D, Karppinen J, Mok F, Fong DY, Luk KD, Cheung KM. A population-based study of juvenile disc degeneration and its association with overweight and obesity, low back pain, and diminished functional status. J Bone Joint Surg Am, 2011, 93(7): 662-670.
5. Gandhi R, Woo KM, Zywiel MG, Rampersaud YR. Metabolic syndrome increases the prevalence of spine osteoarthritis. Orthop Surg, 2014, 6(1): 23-27.
6. Siemionow K, An H, Masuda K, Andersson G, Cs-Szabo G. The effects of age, sex, ethnicity, and spinal level on the rate of intervertebral disc degeneration: a review of 1712 intervertebral discs. Spine (Phila Pa 1976), 2011 Aug 1, 36(17): 1333-1339.
7. Chou D, Samartzis D, Bellabarba C, Patel A, Luk KD, Kisser JM, Skelly AC. Degenerative magnetic resonance imaging changes in patients with chronic low back pain: a systematic review. Spine, 2011, 36(21 Suppl): S43–S53.
8. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. Cell, 2009, 139: 267-284.
9. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci, 2009, 32: 611-618.
10. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science, 2000, 288: 1765-1769.
11. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev, 2014, 66(1): 80-101.
12. Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain, 2013, 154(suppl 1): s10-s28.
13. Loggia ML et al. Evidence for brain glial activation in chronic pain patients. BRAIN. doi: 10.1093/brain/awu377 First published online: 12 January 2015.
14. Давыдов О.С. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования циклооксигеназы 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика, 2016, 8(2): 10-16.
15. Li Y, Liu J, Liu ZZ, Duan DP. Inflammation in low back pain may be detected from the peripheral blood: suggestions for biomarker. Biosci Rep, 2016 Aug 5, 36(4).
16. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev, 2008, 1: CD000396.
17. Kuritzky L., Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. Journal of Pain Research, 2012, 5: 579-590.
18. Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol, 2010 Feb, 381(2): 127-136.
19. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain, 2016, 157: 1634-1644.
20. Данилов А.Б. ЦОГ-зависимые механизмы, участвующие в антиноцицептивном действии НПВП на центральном уровне. Manage Pain, 2014, 3.
21. Kew Y et al. Prevalence and associations of neuropathic pain in a cohort of multi-ethnic Asian low back pain patients. Rheumatol Int, 2017, 37: 633–639.
22. Давыдов О.С. и соавт. Фасеточный синдром. Врач, 2015, 10: 8-14.
23. Manchikanti L. et al. Prevalence of lumbar facet joint pain in chronic low back pain. Pain Physician, 1999, 2(3): 59-64.
24. Schwarzer AC et al. Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain. Annals of the Rheumatic Diseases, 1995, 54: 100-106.
25. Lin HY et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. International Journal of Rheumatic Diseases, 2010, 13: 144–150.
26. Malmstrom K et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placeboand active comparatorcontrolled dose-ranging study. Clin Ther, 2004, 26(5): 667-679.
27. The 2007 Oxford league table of analgesic efficacy http: //www.bandolier.org.uk/booth/painpag/Acutrev/Analgesics/lftab.html.
Review
For citations:
Vorobieva OV. CHRONIC BACK PAIN: FROM PATHOGENETIC CONCEPTS TO THERAPEUTIC STRATEGIES. Meditsinskiy sovet = Medical Council. 2017;(17):36-42. (In Russ.) https://doi.org/10.21518/2079-701X-2017-17-36-42
Views:
729
Email this article 